Zacks Research Has Positive Estimate for EHC FY2025 Earnings

Encompass Health Corporation (NYSE:EHC) – Equities research analysts at Zacks Research lifted their FY2025 earnings per share estimates for shares of Encompass Health in a note issued to investors on Monday, August 18th. Zacks Research analyst Team now expects that the company will post earnings of $5.21 per share for the year, up from their previous estimate of $4.94. The consensus estimate for Encompass Health’s current full-year earnings is $4.80 per share. Zacks Research also issued estimates for Encompass Health’s Q4 2025 earnings at $1.27 EPS, Q1 2026 earnings at $1.40 EPS, Q2 2026 earnings at $1.40 EPS, Q3 2026 earnings at $1.23 EPS, Q4 2026 earnings at $1.43 EPS, FY2026 earnings at $5.46 EPS, Q1 2027 earnings at $1.44 EPS, Q2 2027 earnings at $1.53 EPS and FY2027 earnings at $5.79 EPS.

Encompass Health (NYSE:EHC) last posted its earnings results on Monday, August 4th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.20. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a return on equity of 17.83% and a net margin of 9.22%.The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.11 earnings per share. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen downgraded shares of Encompass Health from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Royal Bank Of Canada raised their price objective on Encompass Health from $110.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, April 28th. Barclays upped their target price on Encompass Health from $118.00 to $129.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Stephens upgraded Encompass Health from an “overweight” rating to a “strong-buy” rating and set a $135.00 price target for the company in a research note on Thursday, June 5th. Finally, KeyCorp boosted their price target on Encompass Health from $122.00 to $135.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $134.00.

Encompass Health Stock Up 1.6%

NYSE:EHC opened at $122.1270 on Tuesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06. The stock has a market capitalization of $12.30 billion, a P/E ratio of 23.90, a P/E/G ratio of 2.10 and a beta of 0.86. The company’s 50-day simple moving average is $116.19 and its 200-day simple moving average is $109.87. Encompass Health has a fifty-two week low of $87.85 and a fifty-two week high of $123.13.

Encompass Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Wednesday, October 1st will be paid a $0.19 dividend. The ex-dividend date is Wednesday, October 1st. This is an increase from Encompass Health’s previous quarterly dividend of $0.17. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.6%. Encompass Health’s dividend payout ratio (DPR) is currently 14.87%.

Institutional Investors Weigh In On Encompass Health

Several hedge funds have recently added to or reduced their stakes in EHC. OneDigital Investment Advisors LLC purchased a new position in shares of Encompass Health during the 1st quarter valued at about $263,000. GAMMA Investing LLC grew its holdings in Encompass Health by 21.5% during the first quarter. GAMMA Investing LLC now owns 2,366 shares of the company’s stock worth $240,000 after acquiring an additional 419 shares during the period. Sequoia Financial Advisors LLC raised its position in Encompass Health by 6.7% during the first quarter. Sequoia Financial Advisors LLC now owns 2,727 shares of the company’s stock valued at $276,000 after acquiring an additional 172 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in Encompass Health by 30.1% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 9,597 shares of the company’s stock valued at $972,000 after acquiring an additional 2,218 shares during the period. Finally, Fifth Third Bancorp boosted its position in Encompass Health by 88.7% in the 1st quarter. Fifth Third Bancorp now owns 4,290 shares of the company’s stock worth $434,000 after purchasing an additional 2,017 shares in the last quarter. 97.25% of the stock is owned by hedge funds and other institutional investors.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.